Epstein Files Search

been marketing and selling Grafix without the typical pm-market review process, under PHS sec. 361 and 21 C.F.R. Part 1271. As we understand, under this regulatory framework the company ... products to market, we note that simply by claiming that they fall under the PHS sec. 361 and 21 C.F.R. Part 1271, is not enough, and still leaves companies ... market segment. We look at the regulatory pathway to qualification under PHS sec. 361 and 21 C.F.R. Part 1271 as it may relate to stem cell therapies. Minimal manipulation